Phase
Condition
Non-hodgkin's Lymphoma
Lymphoma
T-cell Lymphoma
Treatment
Parsaclisib
Chidamide
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age between 18 to 75 years old (including 18 and 75)
Agreeing to sign the written informed consents
Diagnosed as peripheral T-cell lymphoma, including peripheral T-cell lymphoma,unspecified type, anaplastic large cell lymphoma (ALK negative or positive),angioimmunoblastic T-cell lymphoma, enteropathy Related T-cell lymphoma,hepatosplenic T-cell lymphoma, γ/δ T-cell lymphoma, NK/T-cell lymphoma, and othersubtypes of PTCL that the investigator judges to be suitable for participating inthis study
Received at least first-line anti-tumor therapy in the past, whether or notChidamide has been used
Having at least one measurable lesions
World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2
Life expectancy no less than 3 months
enough main organ function
Pregnancy test within 7 days must be negative for women of childbearing period, andappropriate measures should be taken for contraception for women in childbearingperiod during the study and six months after this study
Agreeing to follow the trail protocol requirements
Exclusion
Exclusion Criteria:
Types other than peripheral T-cell lymphoma listed in the enrollment criteria
Diagnosed as central nervous system lymphoma
Received palliative treatment for other malignant tumors in the past 2 years
Uncontrolled active infection
Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heartinfarction less than 6 months
The non-hematological toxicity caused by the previous anti-tumor treatment has notrecovered to ≤1 grade, and the hematological toxicity has not recovered to ≤2 grade
Patients with a history of mental illness
Those who are known to be allergic to the active ingredients or excipients of thedrug parsaclisib and chidamide
Received PI3Kδ inhibitor treatment in the past
Received autologous hematopoietic or allogeneic hematopoietic stem celltransplantation within 3 months
World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) >2
There are factors that affect the absorption of oral drugs
Pregnant or lactating women
Researchers determine unsuited to participate in this trial
Study Design
Connect with a study center
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.